Want to see HK:2696 full AI Analyst Report?
2696 Stock Chart & Stats
HK$84.45
HK$0.05(0.21%)
At close: 4:00 PM EST
HK$84.45
HK$0.05(0.21%)
Day’s Range― - ―
52-Week RangeHK$50.25 - HK$92.00
Previous CloseN/A
Volume849.10K
Average Volume (3M)1.53M
Market Cap
HK$30.34B
Enterprise ValueHK$34.42K
Total Cash (Recent Filing)HK$772.21M
Total Debt (Recent Filing)HK$3.60B
Price to Earnings (P/E)31.5
Beta0.41
Next Earnings
Aug 21, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.52
Shares Outstanding347,786,130
10 Day Avg. Volume1,665,497
30 Day Avg. Volume1,532,406
Financial Highlights & Ratios
PEG Ratio-17.43
Price to Book (P/B)7.08
Price to Sales (P/S)4.21
P/FCF Ratio32.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$110.96Price Target Upside31.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.78
Revenue Forecast (FY)HK$7.64B
Bulls Say, Bears Say
Bulls Say
Sustained Profitability And High Gross MarginsHenlius has maintained positive net income across 2023–2025 with consistently strong gross margins near 69–74%. Durable profitability and high product-level margins support reinvestment into R&D and manufacturing scale, improving resilience versus cyclical revenue swings and enabling longer-term margin expansion initiatives.
Consistent Positive Operating And Free Cash FlowOperating cash flow turned reliably positive from 2021–2025 and FCF was positive in 2023–2025, with 2025 FCF covering a meaningful portion of net income (~74%). Persistent cash generation supports capital investment in biologics capacity and reduces reliance on external financing for commercialization and partnership execution over the medium term.
Integrated Biologics Value Chain And Manufacturing CapabilityHenlius’ integrated model—discovery through manufacturing and commercialization—creates durable competitive advantages: it captures manufacturing margin, accelerates development-to-market timelines, and enables supply agreements and partnerships that diversify revenue streams and strengthen long-term commercial execution.
Bears Say
Meaningful Leverage Despite ImprovementDebt-to-equity improved to ~0.91 in 2025 from higher levels, but leverage remains material for a biotech. Residual indebtedness increases sensitivity to execution hiccups, limits strategic flexibility, and raises refinancing and interest-cost risk that can constrain R&D or commercialization spending during adverse market or clinical outcomes.
2025 Margin Compression And Softer Free Cash FlowMargin compression and an ~8% YoY decline in FCF in 2025 suggest rising costs or higher investment intensity. If sustained, these trends weaken the company’s ability to self-fund growth and reduce earnings quality, making long-term profitability and cash returns more sensitive to pricing, volume, and cost control execution.
Exposure To Pricing, Reimbursement And Tender DynamicsHenlius’ revenue mix—biosimilars and hospital/tender sales—is structurally exposed to pricing pressure, reimbursement policy, and tender outcomes across markets. These industry dynamics can materially affect revenue predictability, margin stability, and the timing of commercial uptake over multiple quarters to years.
Shanghai Henlius Biotech, Inc. Class H News
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$50.25 and its highest was HK$92.00 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$30.34B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date is Aug 21, 2026 which is in 13 days.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Shanghai Henlius Biotech, Inc. Class H released its earnings results on Mar 20, 2026. The company reported HK$0.929 earnings per share for the quarter, beating the consensus estimate of HK$0.639 by HK$0.29.
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate is 0.5.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 347,786,130 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.929 in its last earnings report, beating expectations of HK$0.639. Following the earnings report the stock price went down -1.761%.
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$110.96 (31.39% Upside)
HK$110.96 (31.39% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.14%
Trailing 12-Months
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
2696 Stock 12 Month Forecast
Average Price Target
HK$110.96
▲(31.39% Upside)
Technical Analysis
Innovent Biologics
―
3SBio
―
Wuxi Biologics (Cayman)
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―